Skip to main content

Lixa inks deal to progress trials, raise $28m

1 hour ago

Bookmark

Save articles for future reference.

A company born out of UWA research and seeking to provide a circuit breaker to antimicrobial resistance will look to raise $28 million as it nears a crucial juncture of the preclinical stage.

X

To read our articles you will need to either login or subscribe.